Pharmaceuticals
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...
2025-10-31 21:00
2165
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku,Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the in...
2025-10-31 20:00
1621
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
FRANKFURT, Germany, Oct. 31, 2025 /PRNewswire/ -- From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international commercialization solutions to partners from glo...
2025-10-31 19:50
1726
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
* NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise inGreater China and other Asian markets * Nov...
2025-10-30 16:15
1178
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...
2025-10-30 15:28
1203
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 inGreater China, Singapore, South Korea, and certain Southeast Asian countries. * Under the assigned exclusive license, Everest Medicines will make an upfront payment ofUS$7 million (equivalen...
2025-10-30 11:05
1506
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
* Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. * The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported...
2025-10-30 09:15
1510
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announcedthe initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experi...
2025-10-30 09:00
1512
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared t...
2025-10-30 08:10
1341
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and P...
2025-10-29 23:21
1493
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
* New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide * Strategy centers on broadening access to global capital and innovation through a plannedHong Kong initial public offering (IPO), and holding...
2025-10-29 23:15
2773
IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agree...
2025-10-29 17:01
965
What Hebei Can Offer丨Biomedicine and Beyond
SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...
2025-10-29 15:23
1136
A Breakthrough in Color Measurement Is Coming: The HunterLab Agera L2
RESTON, Va., Oct. 29, 2025 /PRNewswire/ -- A breakthrough in color measurement
is on the horizon. This November,HunterLab
2025-10-29 08:00
1094
Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option
HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering")...
2025-10-29 04:15
2161
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025
/PRNewswire/ -- Harbour BioMed
2025-10-28 22:07
1185
SI GROUP OPENS NEW INNOVATION CENTER
State-of-the-art facility expands company's global research and development
capabilities
THE WOODLANDS, Texas, Oct. 28, 2025 /PRNewswire/ -- SI Group
2025-10-28 20:30
915
Fosun Pharma Announces 2025Q3 Financial Results
Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs ExceedingRMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 60019...
2025-10-28 20:11
1872
Xinhua Silk Road: Innovation, tradition deeply integrated on TCM trade fair in China's Zhangshu City
BEIJING, Oct. 28, 2025 /PRNewswire/ -- China's Zhangshu City, a famed
industrial hub of traditional Chinese medicine (TCM) for centuries, has
actively promoted integration of tradition and innovation forChina's
traditional medicines and medical treatment on its annual TCM fair.
2025-10-28 16:31
910
Samsung Biologics reports third quarter 2025 financial results
* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...
2025-10-28 14:50
1381
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 309 media titles]
2026-01-15 13:00Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 298 media titles]
2026-01-15 10:00Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
5471
